Italian pharmaceutical and carnitine specialist, Sigma-Tau group, which began US operations in 1989, has formed a holding company for its three US companies - Sigma-Tau Pharmaceuticals, Sigma-Tau HealthScience, and Sigma-Tau Research.
The company announced that it has also finalised the appointment of its leadership team for each of the three companies. According to the Sigma-Tau group, the US companies will continue the organisation's three decades of research into carnitine's role in cellular metabolism and the provision of pharmaceutical-quality carnitine that is not genetically modified.
Sigma-Tau is a leading developer of carnitine and ranks among the top 25 niche companies in the world in patent activity, claimed the company.
Each of the three US companies focuses on meeting the needs of their specific patient audiences, said the group. Sigma-Tau Pharmaceuticals is primarily dedicated to the development and production of "orphan'' drugs for small numbers of patients whose pharmaceutical needs might not otherwise be met, Sigma-Tau HealthScience, is composed of two divisions - Consumer Products (focusing on dietary supplements and nutritional foods) and Fine Chemicals and Sigma-Tau Research is developing a series of compounds, in a variety of clinical indications, for the US market.